Payment overview · 2025
General Payments
$2,575.20
120 reported records · 32 companies
Healthcare provider profile · identity verified
Brian Peter First, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SAN DIEGO, CA · NPI 1770531816
Verified facts
What the public records show
CMS Open Payments records show Brian Peter First, M.D. received $2,575.20 in general payments during 2025 across 120 reported records.
Amgen Inc. accounted for 11.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 47 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Prolia, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GENOTROPIN as an associated drug or biological on 864 records involving 515 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Genotropin by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $300.53 | 11.7% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $206.74 | 8.0% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $182.67 | 7.1% | 6 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $164.36 | 6.4% | 6 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $147.02 | 5.7% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $140.94 | 5.5% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $138.10 | 5.4% | 7 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $122.11 | 4.7% | 7 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $94.30 | 3.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $93.77 | 3.6% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $80.18 | 3.1% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$77.85 | 3.0% | 4 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.01 | 3.0% | 5 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $73.78 | 2.9% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $66.97 | 2.6% | 2 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $65.43 | 2.5% | 4 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $56.93 | 2.2% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $54.33 | 2.1% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $51.24 | 2.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.85 | 2.0% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $49.37 | 1.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $42.90 | 1.7% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $32.50 | 1.3% | 1 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $28.48 | 1.1% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $27.56 | 1.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.97 | 0.9% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $23.38 | 0.9% | 1 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $23.24 | 0.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.04 | 0.9% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $21.04 | 0.8% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.94 | 0.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.67 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,575.20 | 120 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $164.36 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $163.27 | 6 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $147.02 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $141.88 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $140.94 | 7 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $133.56 | 6 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $122.11 | 7 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $114.36 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $114.09 | 4 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $94.30 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $94.30 | 4 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $94.30 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $93.77 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $84.50 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $82.47 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $82.47 | 4 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $77.85 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $77.01 | 5 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $73.78 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $68.30 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $66.97 | 2 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $65.43 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.05 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $64.05 | 4 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $56.93 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $51.24 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.85 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $42.90 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $42.90 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $42.90 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.79 | 2 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $32.50 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $29.90 | 2 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $28.48 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $27.56 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.97 | 1 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $23.24 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.44 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $9.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 143 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 188 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 50 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 19 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
50 | 32 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 29 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
143 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
188 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | GENOTROPIN open payments reported associated product |
CMS Open Payments — General Payments 864 supporting records · 515 recipient NPIs · example record 1228794127 |
Genotropin · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 499 | 124 |
| Atorvastatin Calcium | Atorvastatin Calcium | 427 | 124 |
| Metformin Hcl | Metformin Hcl | 312 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 70 |
| Losartan Potassium | Losartan Potassium | 202 | 54 |
| Montelukast Sodium | Montelukast Sodium | 193 | 68 |
| Ozempic | Semaglutide | 188 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 188 | 64 |
| Simvastatin | Simvastatin | 156 | 40 |
| Jardiance | Empagliflozin | 143 | 29 |
| Lisinopril | Lisinopril | 135 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 37 |
| Gabapentin | Gabapentin | 122 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 111 | 28 |
| Alprazolam | Alprazolam | 106 | 28 |
| Trazodone Hcl | Trazodone Hcl | 106 | 27 |
| Glimepiride | Glimepiride | 99 | 29 |
| Eliquis | Apixaban | 92 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 22 |
| Lorazepam | Lorazepam | 85 | 15 |
| Tradjenta | Linagliptin | 85 | 21 |
| Tramadol Hcl | Tramadol Hcl | 77 | 25 |
| Omeprazole | Omeprazole | 74 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 13 |
| Synthroid | Levothyroxine Sodium | 65 | 19 |
| Furosemide | Furosemide | 63 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 60 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 23 |
| Allopurinol | Allopurinol | 55 | 20 |
| Farxiga | Dapagliflozin Propanediol | 54 | 11 |
| Meloxicam | Meloxicam | 51 | 21 |
| Estradiol | Estradiol | 50 | 14 |
| Prolia | Denosumab | 50 | 32 |
| Trulicity | Dulaglutide | 50 | suppressed |
| Xarelto | Rivaroxaban | 49 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 46 | 13 |
| Humalog | Insulin Lispro | 46 | suppressed |
| Carvedilol | Carvedilol | 45 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 13 |
| Telmisartan | Telmisartan | 42 | 11 |
| Azithromycin | Azithromycin | 41 | 36 |
| Ezetimibe | Ezetimibe | 41 | 13 |
| Atenolol | Atenolol | 40 | 13 |
| Methimazole | Methimazole | 40 | 12 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 37 | 29 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Mirtazapine | Mirtazapine | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 36 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 12 |
| Valsartan | Valsartan | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 18 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 16 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Prednisone | Prednisone | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Famotidine | Famotidine | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Repatha Pushtronex | Evolocumab | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Oxtellar Xr | Oxcarbazepine | 13 | suppressed |
| Pentips Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Genotropin | Somatropin | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,575.20 · 120 records | Amgen Inc. | ABRYSVO, AFREZZA, AIRSUPRA, AZMIRO, BREZTRI, COMIRNATY, CRYSVITA, CeQur Simplicity, Dexcom G6 Transmitter, EVENITY, EVKEEZA, Extended Holter, FARXIGA, Flector, GVOKE HYPOPEN, JARDIANCE, KISUNLA, Kerendia, Korlym, LEQVIO, Leqembi, Licart, MINIMED 780G, MOUNJARO, Omnipod, Ozempic, PREVNAR 20, PROLIA, RECORLEV, REPATHA, REZDIFFRA, Rybelsus, TEPEZZA, TRELEGY ELLIPTA, TWIIST, Tirosint, UBRELVY, VEGZELMA, Wegovy, Yorvipath, ZENPEP, ZEPBOUND, ZORYVE, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error